{"title":"ESMO Guidance for reporting oncology real-world evidence (GROW)","authors":"A. S. Motrinchuk, A. A. Kurylev","doi":"10.37489/2782-3784-myrwd-49","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-49","url":null,"abstract":"The European Society for Medical Oncology (ESMO) has produced the very first expert-based guidance for reporting real-world evidence (RWE) studies specifically for oncology. The publication addresses nuances of modern RWE research in oncology and provides a comprehensive list of detailed key recommendations — that have also been transcribed into an interactive informative scoring checklist tool — for full article development in different RWE research scenarios.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"14 7S","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140708192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Current issues related to the off-label use of drugs and their potential solutions","authors":"K. S. Radaeva, S. Mishinova","doi":"10.37489/2782-3784-myrwd-48","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-48","url":null,"abstract":"Relevance. Off-label use of medications is a common practice in clinical settings. To address the growing interest in this issue, the International Society for Pharmacoepidemiology (ISPE) has developed new general guidelines for off-label prescribing in clinical practice that emphasize the importance of evidence-based medicine and promote transparent communication between healthcare professionals and patients.Objective. The aim of this work was to analyze and present key trends for optimizing off-label prescribing decisions based on the ISPE recommendations (2023).Results. The report highlights five main recommendations: seeking strong scientific evidence, including the use of real-world data; using expert knowledge to evaluate and summarize evidence; developing recommendations with rigorous consistency; aligning the use of off-label medications with research; and strengthening collaboration among regulators, researchers, clinicians, and the pharmaceutical industry.Conclusions. A comprehensive approach is required to address the problem of off-label use of medicines. Implementation of these initiatives will reduce the risks associated with off-label use, generate sustainable scientific evidence, and improve the quality of patient care.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140717225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Small interfering RNA: potential in real-world clinical practice","authors":"A. S. Motrinchuk, A. Kasimova","doi":"10.37489/2782-3784-myrwd-46","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-46","url":null,"abstract":"This review describes the basics of protein biosynthesis and RNA interference processes, discusses the useful and unique properties of siRNA therapy, its advantages and disadvantages in comparison with other gene silencing methods, provides a brief overview of technical advances and modifications of siRNA therapy, and characterizes siRNA-registered drugs and agents at different stages of clinical trials.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"25 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140727106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Economics of diabetes mellitus type 2 control based on big data modeling","authors":"S. V. Svetlichnaya, L. Popovich","doi":"10.37489/2782-3784-myrwd-47","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-47","url":null,"abstract":" Background. It has been done previously that the main expenditures in diabetes mellitus type 2 (DM2T) not related with glycemia correction, but they are spending on the cardiovascular diseases (CVDs) of DM2T and indirect costs of CVDs in work-aged patients.Objective. Modelling of potential clinical and economic results of effective programs for DM2T control realizations and their influence on CVDs and mortality in case of HbA1c targets reached.Materials and methods. The Oxford UKPDS model has been used for epidemiologic and economic benefits in cases of decreased CVDs and premature deaths due to more effective control of DM2T. We created 48 cluster groups of patients based on age (less 40 y. o., 40–60 y. o., 60+ y. o.) and HbA1c levels and CVDs anamnesis. The probability of CVDs over 10 years was calculated for each cluster. Subsequently, DALY, YLL, and YLD have also been defined. Average salary, GDP per capita, etc. were used for the analysis.Results. Successful control of DM2T can lead to saving 1.69 billion YLL, or 115.93 years per 100th of people annually. The prognosis for CVD morbidity and mortality decreasing due to more effective DM2T control can decrease DALY loss by 17 %. The effect on the Russian economy in this case can be evaluated as 197,8 billion RUR over 10 years (based on salary level). The benefit in the GDP per capita metric is higher — 213.6 billion RUR annually.Conclusion. Effective methods of DM2T control can reduce the risk of CVD occurrence and progression; therefore, they are economically justified and can be considered as an additional source of budgetary benefits, leading to lower medical care costs.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"41 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140721357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review of the textbook “Clinical and pharmacological characteristics of biotechnological drugs: from classifications to adverse events”","authors":"V. I. Petrov","doi":"10.37489/2782-3784-myrwd-51","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-51","url":null,"abstract":"The European SocIn March 2024, the manual “Clinical and pharmacological characteristics of biotechnological drugs: from classifications to adverse events” was published under general ed. Kolbin A. S. This textbook discusses biotechnological drugs from the perspective of clinical pharmacology. Basic definitions and classifications are given. Pharmacodynamics, pharmacokinetics and adverse events are reviewed. Examples of interactions between biotechnological drugs and small molecules are presented. A separate chapter examines the interchangeability of biological products — from basic terms and definitions of the concept of biosimilarity to regulatory aspects. The Appendix provides examples of clinical applications of therapeutic proteins. The manual is intended for students, residents, graduate students, clinical pharmacologists and physicians of other specialties.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"44 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140750311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-world data studies in oncology: analysis of the Russian publications","authors":"V. Achikyan, A. A. Kurylev, A. Kolbin","doi":"10.37489/2782-3784-myrwd-50","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-50","url":null,"abstract":"Background. Real-world data studies are an important source of knowledge on malignant tumors and their treatment. This knowledge is a tool for making decisions by health care professionals and patients. Regarding this, authors conducted literature search to identify real-world data studies published in the Russian scientific journals.Objective. The study aim was finding and analyzing publications on real-world evidence studies in oncology therapeutic area.Materials and methods. Full-text articles published in the Russian peer-reviewed medical scientific journals of 2022 and 2023 were systematically relieved and analyzed.Results. 119 publications were selected. The following types of study data were identified: 1) data on patients management practice; 2) survival and other oncology outcomes regardless of treatment approach; 3) survival and other oncology outcomes depending on treatment approach; 4) efficacy of a concrete therapy; 5) treatment safety (toxicity) data; 6) clinical and demographic prognostic factors; 7) tumor (morphological, molecular and genetic) prognostic factors; 8) tumor characteristics (morphological, molecular and genetic) regardless of their prognostic significance; 9) oncology disease characteristic (e. g., comorbidities) regardless of its prognostic significance. The most common types of study data were the following: clinical and demographic prognostic factors — 24 studies; tumor (morphological, molecular and genetic) prognostic factors — 36 studies; tumor characteristics (morphological, molecular and genetic) regardless of their prognostic significance — 38 studies.Conclusion. The modern real-world data studies in oncology therapeutic area are a very important source of knowledge on malignant tumors and their treatment.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"159 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140750697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Resolution based on the results of the IV annual scientific-practical conference \"Real clinical practice. Modernity and the future\"","authors":"A. Kolbin","doi":"10.37489/2782-3784-myrwd-41","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-41","url":null,"abstract":"On September 28, 2023, the IV annual scientific-practical conference with international participation \"Real clinical Practice. Modernity and the future\" were organized and held. The theme of the conference brings together leading experts in the field of RWD/RWE. The participants of the conference discussed the research tools of real clinical practice, the confirming value of RWE in modern medicine, legislation, and global perspectives in the world, Russian Federation, and the EAEU. A total of 27 reports were heard at the conference. Based on the results of the conference, a Resolution was developed, the text of which we offer you to familiarize yourself with. ","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"27 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138949801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Considerations for the design and conduct of externally controlled trials for drug and biological products","authors":"A. S. Motrinchuk, D. Belousov","doi":"10.37489/2782-3784-myrwd-45","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-45","url":null,"abstract":"This guidance provides recommendations to sponsors and investigators considering the use of externally controlled clinical trials to provide evidence of the safety and effectiveness of a drug product. In an externally controlled trial, outcomes in participants receiving the test treatment according to a protocol are compared with outcomes in a group of people external to the trial who had not received the same treatment. The external control arm can be a group of people, treated or untreated, from an earlier time (historical control), or it can be a group of people, treated or untreated, during the same period (concurrent control) but in another setting. The guidance addresses considerations for the design and analysis of externally controlled trials to study the effectiveness and safety of drugs, including discussion of threats to the validity of trial results from potential bias. Although various sources of data can serve as the control arm in an externally controlled trial, this guidance focuses on the use of patient-level data from other clinical trials or from real-world data (RWD) sources, such as registries, electronic health records, and medical claims. The guidance also describes considerations related to communicating with the FDA and ensuring access by the FDA to data from an externally controlled trial. This guidance does not address other types of external controls, such as using summary-level estimates instead of patient-level data. This guidance does not discuss details of the design and analysis of a natural history study nor the reliability and relevance of various sources of RWD that could be used in an externally controlled trial. Finally, this guidance also does not discuss considerations for using external control data to supplement a control arm in a traditional randomized controlled clinical trial. In general, FDA guidance documents do not establish legally enforceable responsibilities. Instead, guidance describes the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"56 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138952546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Proposed changes ICER 2023 value assessment framework","authors":"I. R. Svechkareva, A. A. Kurylev","doi":"10.37489/2782-3784-myrwd-44","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-44","url":null,"abstract":"Since 2006, the Institute for Clinical and Economic Review (ICER) in the United States has assessed the clinical and economic value of innovative medical technologies and made pricing recommendations with the goal of achieving “sustainable access to highly effective treatments for all patients”. The methodological framework developed by ICER assesses the longterm economic value of health interventions and their availability in the shortest possible time.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"35 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138950017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review of data sources used in real-world traumatology and orthopedic","authors":"I. U. Zolotukhina, A. R. Kasimova","doi":"10.37489/2782-3784-myrwd-42","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-42","url":null,"abstract":"Real-world data (RWD) play an increasingly important role in traumatology and orthopedics, as evidenced by the rapidly growing number of publications using registry, administrative, and other databases. Each type of RWD source has its own strengths and weaknesses, as does each database. Before using a particular RWD source, a researcher should understand its advantages and limitations. Careful attention to data quality and the use of appropriate analytical methods may help alleviate concerns regarding the validity of orthopedic studies using RWD. This article describes the main types of RWD used in traumatology and orthopedics and provides a brief description of RWD. ","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"40 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138949014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}